Prognostic Significance of Plasma Heparan Sulphate Degradation Products in Multi-Organ Dysfunction Syndrome
DOI:
https://doi.org/10.5281/zenodo.22644010Keywords:
heparan sulphate, endothelial glycocalyx, multi-organ dysfunction syndrome, syndecan-1, heparanaseAbstract
Background: Multi-organ dysfunction syndrome (MODS) remains the principal proximate cause of death in critically ill patients
with sepsis, severe trauma, and major surgical or burn injury. Conventional organ-specific markers detect dysfunction only after
substantial functional loss has occurred, motivating interest in upstream markers of the shared vascular injury that precedes
clinical organ failure. The endothelial glycocalyx, whose dominant glycosaminoglycan is heparan sulphate, is enzymatically
degraded early in critical illness, releasing heparan sulphate fragments and its core proteoglycan syndecan-1 into the circulation.
Objective: To synthesise the published literature on circulating heparan sulphate degradation products, principally shed syndecan-1
and free heparan sulphate/heparanase activity, as prognostic biomarkers of MODS severity and mortality across sepsis, trauma,
burns, cardiac surgery, and paediatric critical illness. Methods: A narrative review of mechanistic, epidemiological, and clinical
cohort literature addressing heparan sulphate biology, heparanase-mediated glycocalyx shedding, and the prognostic performance
of heparan sulphate-related biomarkers for multi-organ dysfunction and mortality in critically ill populations, identified through
structured literature searching and verified against primary sources. Findings: Circulating syndecan-1 and heparan sulphate rise
early after the onset of critical illness and correlate with contemporaneous and subsequent Sequential Organ Failure Assessment
(SOFA) scores across sepsis, trauma, burn, and cardiac surgical cohorts. Meta-analyses of syndecan-1 in sepsis report consistent
associations with septic shock, acute kidney injury, coagulopathy, and mortality. A trial-embedded analysis of the CLOVERS cohort
demonstrated graded, dose-dependent relationships between circulating glycosaminoglycan degradation products and 90-day
mortality that also modified the comparative effectiveness of liberal versus restrictive fluid strategies. Comparable associations are
reported in paediatric acute respiratory distress syndrome, pancreatitis-associated MODS, burn and trauma-related
endotheliopathy, cardiac surgery, and COVID-19-related endotheliopathy, and mechanistic work implicates heparanase-1 as the
principal sheddase linking systemic inflammation to glycocalyx injury. Conclusions: Circulating heparan sulphate degradation
products constitute biologically plausible, reproducible, and prognostically informative biomarkers of MODS across diverse critical
illness phenotypes, with the strongest evidence for syndecan-1 in sepsis. Assay standardisation, external validation of cut-points,
and prospective trials testing biomarker-informed management are needed before these markers can be incorporated into routine
multi-organ dysfunction risk stratification.
References
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8):801-810, DOI:10.1001/jama.2016.0287.
Soo A, Zuege DJ, Fick GH, Niven DJ, Berthiaume LR, Stelfox HT, Doig CJ (2019) Describing organ dysfunction in the intensive care unit: a cohort study. Critical Care, 23:186, DOI:10.1186/s13054-019-2459-9.
Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, oude Egbrink MGA (2007) The endothelial glycocalyx: composition, functions, and visualization. Pflügers Archiv - European Journal of Physiology, 454(3):345-359, DOI:10.1007/s00424-007-0212-8.
Uchimido R, Schmidt EP, Shapiro NI (2019) The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Critical Care, 23:16, DOI:10.1186/s13054-018-2292-6.
Iba T, Levy JH (2019) Derangement of the endothelial glycocalyx in sepsis. Journal of Thrombosis and Haemostasis, 17(2):283-294, DOI:10.1111/jth.14371.
Li H, Wen H, Liu J, Zhang Y, Zhao G, Wang X (2025) The glycocalyx: a key target for treatment of severe acute pancreatitis-associated multiple organ dysfunction syndrome. Human Cell, 38:107, DOI:10.1007/s13577-025-01227-6.
Martin L, Zechendorf E, Schröder K, Horowitz JC, Ziegler J, Kraemer S, Marx G, Simon TP, Schuerholz T (2022) The potential impact of heparanase activity and endothelial damage in COVID-19 disease. Journal of Clinical Medicine, 11(18):5261, DOI:10.3390/jcm11185261.
Suzuki K, Okada H, Sumi K, Tomita H, Kobayashi R, Ishihara T, Mizuno T, Yamaji F, Suzuki K, Muraki I, Tada M, Kobayashi H, Kanda N, Wakabayashi S, Nishio Y, Okamoto A, Kanabuchi Y, Doi T (2021) Serum syndecan-1 reflects organ dysfunction in critically ill patients. Scientific Reports, 11:8864, DOI:10.1038/s41598-021-88303-7.
Wang M, He M, Hong L, Shen Y, Wang Q, Sun Y (2026) Association between circulating biomarkers of endothelial glycocalyx degradation and postoperative acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. Frontiers in Surgery, 13:1863142, DOI:10.3389/fsurg.2026.1863142.
Morgan KM, Abou-Khalil E, Gaines BA, Leeper CM (2024) Endotheliopathy of trauma in children: the association of syndecan-1 with injury and poor outcomes. Journal of Trauma and Acute Care Surgery, 96(5), DOI:10.1097/TA.0000000000004229.
Xu D, Dong C, Zhao Z, Hou S (2026) Syndecan-1 as a biomarker of endothelial glycocalyx injury in sepsis: a meta-analysis of associations with shock, organ complications and mortality. Postgraduate Medical Journal, DOI:10.1093/postmj/qgag053.
Sun T, Wang Y, Wu X, Cai Y, Zhai T, Zhan Q (2022) Prognostic value of syndecan-1 in the prediction of sepsis-related complications and mortality: a meta-analysis. Frontiers in Public Health, 10:870065, DOI:10.3389/fpubh.2022.870065.
Daniyarova KR, Sarkulova ZN, Tamadon A, Berdibayeva RS, Kamysbayev MK, Tazhieva NB (2025) Glycocalyx and endothelial biomarkers as prognostic indicators in sepsis: a systematic review and meta-analysis. MicrobiologyOpen, 14(6):e70155, DOI:10.1002/mbo3.70155.
Qian X, Lui KY, Hu X, Chen Y, Zhou Y, Wang H (2025) Dynamic changes and prognosis value of plasma syndecan-1 and different microcirculatory parameters in sepsis: a prospective observational study. World Journal of Surgery, 49, DOI:10.1002/wjs.12452.
Murphy LS, Wickersham N, McNeil JB, Shaver CM, May AK, Bastarache JA, Ware LB (2017) Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunction. Annals of Intensive Care, 7:102, DOI:10.1186/s13613-017-0325-y.
Kajita Y, Terashima T, Mori H, Islam MM, Irahara T, Tsuda M, Kano H, Takeyama N (2021) A longitudinal change of syndecan-1 predicts risk of acute respiratory distress syndrome and cumulative fluid balance in patients with septic shock: a preliminary study. Journal of Intensive Care, 9:27, DOI:10.1186/s40560-021-00543-x.
Benatti MN, Fabro AT, Miranda CH (2020) Endothelial glycocalyx shedding in the acute respiratory distress syndrome after flu syndrome. Journal of Intensive Care, 8:72, DOI:10.1186/s40560-020-00488-7.
Sallee CJ, Maddux AB, Hippensteel JA, Markovic D, Oshima K, Schwingshackl A, Mourani PM, Schmidt EP, Sapru A (2024) Circulating heparan sulfate profiles in pediatric acute respiratory distress syndrome. Shock, 62(4):496-504, DOI:10.1097/shk.0000000000002421.
Sallee CJ, Maddux AB, Hippensteel JA, Markovic D, Wang Z, Liu J, Oshima K, Richter RP, Schwingshackl A, Mourani PM, Elashoff D, Schmidt EP, Sapru A (2026) Plasma heparan sulfate structural variation and phenotypic heterogeneity in pediatric acute respiratory distress syndrome. Scientific Reports, 16, DOI:10.1038/s41598-026-59291-3.
Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR (2011) A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Annals of Surgery, 254(2):194-200, DOI:10.1097/SLA.0b013e318226113d.
Gonzalez Rodriguez E, Ostrowski SR, Cardenas JC, Baer LA, Tomasek JS, Henriksen HH, Stensballe J, Cotton BA, Holcomb JB, Johansson PI, Wade CE (2017) Syndecan-1: a quantitative marker for the endotheliopathy of trauma. Journal of the American College of Surgeons, 225(3):419-427, DOI:10.1016/j.jamcollsurg.2017.05.012.
Oshima K, Yan B, Tao R, Uchimido R, Kingsley P, Schmidt EP (2026) Plasma chondroitin sulfate predicts the effectiveness of fluid resuscitation strategies in patients with sepsis. Journal of Clinical Investigation, 136(7), DOI:10.1172/JCI202480.
